NASDAQ OMX

Zinpro Corporation Launches Zinpro Discovery Foundation

31.5.2017 18:55 | NASDAQ OMX

Dela

Its mission: to discover, research, or develop solutions to improve human and animal wellness

EDEN PRAIRIE, Minn., May 31, 2017 (GLOBE NEWSWIRE) -- Zinpro Corporation has announced the launch of the Zinpro Discovery Foundation, a U.S.-tax-exempt 501(c) (3) nonprofit organization whose mission is to discover, research, or develop solutions to improve human and animal wellness across the globe.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3a52721d-7a4c-4be7-b0bd-7380090f7406

"Zinpro Corporation pioneered the research and development of Performance Minerals® more than 45 years ago," says William Scrimgeour, president and COO. "Over the years, our many nutritional and business solutions have resulted in significant improvements in animal wellness and performance. However, our global leadership in animal mineral nutrition also comes with the responsibility to ensure our research is used to benefit society as much as possible. With this goal in mind, we have collaborated with leaders outside Zinpro to create the Zinpro Discovery Foundation."

Nutritionists have long known that trace mineral nutrition is essential to health for both humans and animals. For example, zinc deficiency negatively affects up to 2 billion people worldwide.1 For so many people across the globe, the difference between being healthy and unhealthy lies in only a few milligrams of zinc. The multiple systemic effects from zinc deficiency include growth retardation, weight loss, infertility, hair loss, mental and emotional disorder, impaired immune function and skin lesions.

Zinc is just one essential trace mineral that shows benefits when supplemented to both animal and human diets. Other essential trace minerals, such as copper, cobalt, manganese, iron, chromium, selenium and iodine, also play key roles that benefit animal and human health.

"Since our research in animal nutrition has great potential to pave the way for breakthroughs in human health, we started a nonprofit organization to make that possible, and the Zinpro Discovery Foundation is the culmination of our efforts," Scrimgeour says.

The Zinpro Discovery Foundation welcomes donations to help raise awareness and knowledge about trace mineral deficiencies and how to improve human and animal wellness. Educational and research grants are allocated by a board of directors. The donation goal for 2017 is $1 million (USD) in educational and research grants.

Grants are available to researchers and organizations through an application process that starts online at zinprodiscoveryfoundation.org. Details of the request include how a researcher or an organization would spend the funds if the grant is received. Requests are evaluated based on the applicant's stated problem statements and project goals.

To obtain additional information, including regular updates on active grants and recent donations, check online at zinprodiscoveryfoundation.org.

1. Data are based on the composite nutrient composition database, IZINCG physiological requirements and the Miller Equation to estimate zinc absorption and an assumed 25% inter-individual variation in zinc intake. Data are for the 2005 time frame (2003-2007). To confirm the prevalence of zinc deficiency, it is recommended to assess plasma zinc concentration and/or dietary zinc intake in countries identified at high risk of zinc deficiency based on a high stunting prevalence or high prevalence of dietary zinc availability (http://www.izincg.org/).

About Zinpro Corporation

More than 45 years ago, Zinpro Corporation pioneered the research and development of Performance Minerals®. As a family-owned, privately-held company, Zinpro Corporation's steady growth has come as a result of quality products, quality people and a focus on one thing: performance trace minerals for exceptional animal nutrition. Today, the company has regional sales offices located in nine countries and markets its products in more than 70 countries worldwide. For more information, visit  zinpro.com , or call +1 952-983-4000.

Performance Minerals® is a registered trademark of Zinpro Corporation. ©2017 Zinpro Corp. All rights reserved.

For more information, contact:
John Pocock
Corporate Communications Specialist
Zinpro Corporation
+1 952-983-3937
jpocock@zinpro.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zinpro Corporation via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressmeddelande

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressmeddelande

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressmeddelande

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressmeddelande

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38Pressmeddelande

NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical

CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00Pressmeddelande

CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum